Psilocybin-Based Selective Mutism Treatment With NAC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for selective mutism, such as selective serotonin reuptake inhibitors (SSRIs), have shown long-term adverse effects and limited efficacy, and there is a need for alternative methods to alleviate symptoms of selective mutism in children.
Innovation Solution
Administering a serotonergic psychedelic agent, such as psilocybin or a psilocybin-derived agent, alone or in combination with N-acetylcysteine (NAC), to trigger non-ordinary states of consciousness and modulate serotonin receptors, thereby alleviating symptoms of selective mutism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SSRIs are used to treat selective mutism, then some symptomatic relief may be achieved, but long-term adverse effects and limited efficacy occur
Solution Approach 1:
The patent changes the pharmacological parameter from SSRIs to serotonergic psychedelic agents (psilocybin and psilocin), which have different mechanisms of action on serotonin receptors. This parameter change aims to achieve therapeutic effects while avoiding the long-term adverse effects associated with SSRIs, including adult anxiety/depression-like phenotypes and persistent serotonin transporter blocking
Solution Approach 2:
The patent introduces N-acetylcysteine (NAC) as an intermediary substance that enhances the therapeutic effect of serotonergic psychedelic agents. NAC acts as a mediator that potentiates the anxiety-reducing and communication-improving effects while helping to avoid adverse effects through its antioxidant and glutamatergic modulating properties
2Ease of manufacture
If SSRIs are administered to children with selective mutism, then treatment is provided, but long-term detrimental mental health effects are induced
Solution Approach 1:
The patent changes the treatment parameter from SSRIs to serotonergic psychedelic agents with different receptor profiles and mechanisms. Psilocybin and psilocin directly activate 5HT1B receptors and modulate serotonin release differently than SSRIs, avoiding persistent serotonin transporter blocking and long-term detrimental effects on adult mental health
Solution Approach 2:
The patent employs periodic or controlled administration of serotonergic psychedelic agents rather than continuous SSRI treatment. The treatment involves specific dosing regimens where psilocybin is administered in controlled sessions, allowing the brain to reset serotonin transporter function between treatments, thus avoiding long-term detrimental effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of a serotonergic psychedelic agent and NAC has shown potential in reducing anxiety and improving communication in children with selective mutism, potentially avoiding the adverse effects associated with SSRIs.
Implementation Method 1
Administering a serotonergic psychedelic agent, such as psilocybin or a psilocybin-derived agent, alone or in combination with N-acetylcysteine (NAC), to trigger non-ordinary states of consciousness and modulate serotonin receptors
Data Source
AI summary
Methods and compositions for treating or alleviating symptoms of selective mutism in a human subject with a serotonergic psychedelic agent alone or in combination with N-acetylcysteine are provided.